Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
- Conditions
- Peripheral Arterial Disease
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 125
- Registration Number
- NCT00368797
- Locations
- 🇮🇹
Istituto Dermopatico dell'Immacolata, Roma, Italy
🇩🇪Klinikum Karlsbad-Langensteinbach, Karlsbad, Germany
🇨🇭Universitätsklinik, Bern, Switzerland
Dose-Exposure-Response in Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type I
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2006-08-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00368394
- Locations
- 🇩🇪
Sanofi-Aventis, Neuss, Germany
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 241
- Registration Number
- NCT00366795
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumabDrug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumabDrug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumabDrug: Docetaxel (T) + bevacizumabDrug: Bevacizumab and trastuzumab maintenance therapyDrug: Bevacizumab maintenance therapy
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 214
- Registration Number
- NCT00365365
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 73
- Registration Number
- NCT00364611
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
- Conditions
- Hypertension
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 281
- Registration Number
- NCT00362037
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt
I PREVENT - Irbesartan In Hypertensive Diabetic Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 797
- Registration Number
- NCT00362258
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt
Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00361738
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
- Conditions
- Depressive Disorder
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2009-01-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 324
- Registration Number
- NCT00361491
- Locations
- 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation
Insulin Glulisine in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT00360698
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
🇬🇧Sanofi-aventis, Guildford, United Kingdom